R&D Payments Clause Samples

The R&D Payments clause defines the terms and conditions under which payments are made for research and development activities between the parties. Typically, it outlines the payment schedule, milestones or deliverables that trigger payments, and any documentation or reporting requirements needed to support payment requests. This clause ensures that both parties have a clear understanding of when and how payments will be made, thereby reducing the risk of disputes and ensuring that funding for R&D activities is provided in a timely and predictable manner.
POPULAR SAMPLE Copied 1 times
R&D Payments. For the first ten (10) full Calendar Quarters after the Effective Date, G▇▇▇▇▇▇▇ shall pay to Palomar for each such Calendar Quarter seven hundred thousand dollars (US $700,000) to support the R&D Activities (each such payment, an “R&D Payment” and collectively the “R&D Payments”) in accordance with Section 1.3(b)(iii). For the avoidance of doubt, G▇▇▇▇▇▇▇ shall be required to pay to Palomar seven million dollars (US $7,000,000) in the aggregate, and no more than seven million five hundred thousand dollars (US $7,000,000) in the aggregate, unless otherwise expressly provided herein, in Section 14.2(d), or as the parties may otherwise agree, in connection with the R&D Program (which amount shall be inclusive of the five hundred thousand dollar (US $500,000) payment made by G▇▇▇▇▇▇▇ to Palomar pursuant to Section 6.1(a) and credited against payments made in connection with the R&D Program as provided in that Section). In the event that this Agreement is terminated by G▇▇▇▇▇▇▇ pursuant to Section 10.4(a) before the final R&D payment becomes due, G▇▇▇▇▇▇▇’▇ shall be obligated to make R&D Payments to Palomar in the amount of four million five hundred thousand dollars ($4,500,000) in the aggregate (against which amount the five hundred thousand dollar ($500,000) payment made by G▇▇▇▇▇▇▇ to Palomar pursuant to Section 6.1(a) shall be credited). In the event that this Agreement is terminated by G▇▇▇▇▇▇▇ pursuant to Section 10.4(b) before the final R&D payment becomes due, G▇▇▇▇▇▇▇ shall be obligated to make R&D Payments to Palomar with respect to the two (2) Calendar Quarters after the Calendar Quarter in which G▇▇▇▇▇▇▇ provides to Palomar written notice of such termination (against which amounts the five hundred thousand dollar ($500,000) payment made by G▇▇▇▇▇▇▇ to Palomar pursuant to Section 6.1(a) shall be credited). In the event that this Agreement is terminated by G▇▇▇▇▇▇▇ pursuant to Section 10.4(d) or by Palomar pursuant to Section 10.3 before the final R&D Payment becomes due, G▇▇▇▇▇▇▇ shall be obligated to pay Palomar all remaining R&D Payments (against which remaining amount the five hundred thousand dollar ($500,000) payment made by G▇▇▇▇▇▇▇ to Palomar pursuant to Section 6.1(a) shall be credited). In the event that this Agreement is terminated by G▇▇▇▇▇▇▇ pursuant to Section 10.3 for Palomar’s uncured material breach before the final R&D Payment becomes due, G▇▇▇▇▇▇▇ shall have no further obligation from and after the date on which G▇▇▇▇▇▇▇ provides t...
View SourceView Similar (3)
R&D Payments. For the first thirteen (13) full Calendar Quarters after the Effective Date, G▇▇▇▇▇▇▇ shall pay to Palomar for each such Calendar Quarter seven hundred thousand dollars (US$700,000) to support the R&D Activities (each such payment, an “R&D Payment” and collectively the “R&D Payments”) in accordance with Section 1.3(b)(iii). For the avoidance of doubt, G▇▇▇▇▇▇▇ shall be required to pay to Palomar nine million, one hundred thousand dollars (US$9,100,000) in the aggregate, and no more than nine million, one hundred thousand dollars (US$9,100,000) hi the aggregate, unless otherwise expressly provided herein, hi Section 14.2(d), or as the parties may otherwise agree, in connection with the R&D Program (which amount shall be inclusive of the five hundred thousand dollar (US$500,000) made by G▇▇▇▇▇▇▇ to Palomar pursuant to Section 6.1 (a) and credited against payments made in connection with the R&D Program as provided in that Section).”
View SourceView Similar (3)
R&D Payments. Purchaser shall pay to Seller all amounts received by Net2Edge that constitute R&D Relief (collectively, the “R&D Payments”). Purchaser shall pay to Seller all R&D Payments no later than ten (10) days following the date on which Net2Edge receives such R&D Payments. Purchaser shall cause Net2Edge to make such elections and take such actions as Seller may reasonably request to claim any R&D Relief, provided that Purchaser shall not be required to take any action that Purchaser reasonably determines would violate any applicable Law. Purchaser shall not be required to make payment to Seller more than once in respect of any R&D Relief.
View SourceView Similar (2)
R&D Payments. In further consideration of InSite's grant of rights to P&U hereunder, including the licenses set forth in Article 2, and subject to the terms and conditions of this Agreement, P&U will pay InSite as follows: (a) in United States currency by wire transfer to an account designated by InSite, on *. (b) in United States currency by wire transfer to an account designated by InSite, on *. (c) in United States currency by wire transfer to an account designated by InSite, on *. (d) Subject to Section 4.1(b), InSite shall devote and use the research and development payments received under this Section 3.2 solely for the purpose of covering internal and external costs associated with further developing the ISV-900 Technology. (e) Any additional research and development payments related to the commercialization of the Product shall be determined by the Development Committee. The failure of the Development Committee to agree on any additional research and development payments shall not affect or impair the rights granted to P&U hereunder.
View Source
R&D Payments. During the Phase 3 Clinical Trial term and subject to Section 6.2, AnGes shall make non-refundable and non-creditable (except as provided in Section 6.2(a) and 6.2(b)) payments to Vical (each, an “Installment” and collectively, the “R&D Payments”), all of which shall be used exclusively to pay for or reimburse Project Costs, in the amounts set forth below: (i) On the Effective Date, $6,900,000, pursuant to the Stock Purchase Agreement. (ii) A second Installment of [ *** ] in cash. (iii) A third Installment of [ *** ] in cash and [ *** ], pursuant to the Stock Purchase Agreement. (iv) A fourth Installment of [ *** ] in cash. (v) A fifth Installment of [ *** ] in cash. (vi) [ *** ] in cash.
View Source
R&D Payments. Licensee shall in addition make R&D Payments to MGI as follows: (i. two (2) days after the Effective Date of this Agreement, Licensee shall pay MGI *;
View Source
R&D Payments. During the Phase 3 Clinical Trial term and subject to Section 6.2, AnGes shall make non-refundable and non-creditable (except as provided in Section 6.2(a) and 6.2(b)) payments to Vical (each, an “Installment” and collectively, the “R&D Payments”), all of which shall be used exclusively to pay for or reimburse actual and documented costs of research and development activities of Vical and its subcontractors in performance of the Phase 3 Clinical Trial, in the amounts and at the times set forth below: (i) On the Effective Date, $6,900,000, pursuant to the Stock Purchase Agreement. (ii) By no later than [***], [***] in cash. (iii) By no later than [***], [***] in cash, and by no later than [***], $3,950,000, pursuant to the Stock Purchase Agreement. (iv) By no later than [***], [***] in cash. (v) By no later than [***], [***] in cash. (vi) By no later than [***], [***] in cash. Notwithstanding the foregoing schedule of Installments, if the Phase 3 Clinical Trial progresses at a faster rate than set forth in the Project Plan, the parties agree to discuss in good faith an acceleration of the schedule of Installments set forth in this Section 6.1(a).
View Source
R&D Payments. For the first ten (10) full Calendar Quarters after the Effective Date, ▇▇▇▇▇▇▇▇ shall pay to Palomar for each such Calendar Quarter seven hundred thousand dollars (US $700,000) to support the R&D Activities (each such payment, an “R&D Payment” and collectively the “R&D Payments”) in accordance with Section 1.3(b)(iii). For the avoidance of doubt, ▇▇▇▇▇▇▇▇ shall be required to pay to Palomar seven million dollars (US $7,000,000) in the aggregate, and no more than seven million five hundred thousand dollars (US $7,000,000) in the aggregate, unless otherwise expressly provided herein, in Section 14.2(d), or as the parties may otherwise agree, in connection with the R&D Program (which amount shall be inclusive of the five hundred thousand dollar (US $500,000) payment made by ▇▇▇▇▇▇▇▇ to Palomar pursuant to Section 6.1(a) and credited against payments made in connection with the R&D Program as provided in that Section). In the event that this Agreement is terminated by ▇▇▇▇▇▇▇▇ pursuant to Section 10.4(a) before the final R&D payment becomes due, ▇▇▇▇▇▇▇▇’▇ shall be obligated to make R&D Payments to Palomar in the amount of four million five hundred thousand dollars ($4,500,000) in the aggregate (against which amount the five hundred thousand -29-
View Source
R&D Payments 
View SourceView Similar (3)

Related to R&D Payments

  • Withheld Payments At any time, the Receiver or the Corporation may, in its discretion, determine that all or any portion of any deposit balance assumed by the Assuming Institution pursuant to this Agreement does not constitute a "Deposit" (or otherwise, in its discretion, determine that it is the best interest of the Receiver or Corporation to withhold all or any portion of any deposit), and may direct the Assuming Institution to withhold payment of all or any portion of any such deposit balance. Upon such direction, the Assuming Institution agrees to hold such deposit and not to make any payment of such deposit balance to or on behalf of the depositor, or to itself, whether by way of transfer, set-off, or otherwise. The Assuming Institution agrees to maintain the "withheld payment" status of any such deposit balance until directed in writing by the Receiver or the Corporation as to its disposition. At the direction of the Receiver or the Corporation, the Assuming Institution shall return all or any portion of such deposit balance to the Receiver or the Corporation, as appropriate, and thereupon the Assuming Institution shall be discharged from any further liability to such depositor with respect to such returned deposit balance. If such deposit balance has been paid to the depositor prior to a demand for return by the Corporation or the Receiver, and payment of such deposit balance had not been previously withheld pursuant to this Section, the Assuming Institution shall not be obligated to return such deposit balance to the Receiver or the Corporation. The Assuming Institution shall be obligated to reimburse the Corporation or the Receiver, as the case may be, for the amount of any deposit balance or portion thereof paid by the Assuming Institution in contravention of any previous direction to withhold payment of such deposit balance or return such deposit balance the payment of which was withheld pursuant to this Section.

  • Yield Payments On the Settlement Date for each Purchaser Interest of the Financial Institutions, Seller shall pay to the Agent (for the benefit of the Financial Institutions) an aggregate amount equal to the accrued and unpaid Yield for the entire Tranche Period of each such Purchaser Interest in accordance with Article II.

  • Refused Payments We reserve the right to refuse to pay any Receiver. We will attempt to notify the Sender promptly if we decide to refuse to pay a Receiver designated by the Sender. This notification is not required if you attempt to make a prohibited payment under this Agreement.

  • ▇▇▇▇▇▇▇▇ and Payments ▇▇▇▇▇▇▇▇ and payments shall be sent to the addresses set out in Appendix F hereto.

  • Deferred Payments “Deferred Payments” means any severance pay or benefits to be paid or provided to Executive (or Executive’s estate or beneficiaries) pursuant to this Agreement and any other severance payments or separation benefits to be paid or provided to Executive (or Executive’s estate or beneficiaries), that in each case, when considered together, are considered deferred compensation under Section 409A.